Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy after Breast Cancer

  • Chapter
Women’s Health and Menopause

Part of the book series: Medical Science Symposia Series ((MSSS,volume 11))

  • 106 Accesses

Abstract

At present, the use of postmenopausal hormone replacement therapy (HRT) in women with a history of breast cancer is controversial [1–10]. HRT has long been considered to be contraindicated in postmenopausal women with a history of this disease, since estrogen could exert a stimulating effect on dormant residual breast cancer cells somewhere in the body or on the epithelium of the contralateral breast. Recently, however, questions have been raised as to whether this is correct, in view of the impact HRT can have on quality of life in breast cancer survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. DiSaia PJ. Hormone-replacement therapy in patients with breast cancer: A reappraisal. Cancer 1993;71:1490–1500.

    Article  PubMed  CAS  Google Scholar 

  2. Marchant DJ. Estrogen-replacement therapy after breast cancer: Risks versus benefits. Cancer 1993;71:2169–76.

    Article  PubMed  CAS  Google Scholar 

  3. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372–75.

    Article  PubMed  CAS  Google Scholar 

  4. DiSaia PJ, Odicino F, Grosen EA, et al. Hormone replacement therapy in breast cancer. The Lancet 1993;342:1232.

    Article  CAS  Google Scholar 

  5. Lobo RA. Hormone replacement therapy. Oestrogen replacement after treatment for breast cancer? The Lancet 1993;341:1313–14.

    Article  CAS  Google Scholar 

  6. McNeil C. ERT for breast cancer survivors: A hot debate runs on little data. JNCI 1995:87; 1047–50.

    Article  PubMed  CAS  Google Scholar 

  7. Isaacs CJ, Swain SM. Hormone replacement therapy in women with a history of breast carcinoma. Review. Hemat Oncol Clin North Am 1994;8:179–95.

    CAS  Google Scholar 

  8. Sands R, Boshoff C, Jones A, Studd J. Hormone replacement therapy after a diagnosis of breast cancer. Menopause 1995;2:73–80.

    Article  Google Scholar 

  9. Kenemans P and Scheele F. Hormone replacement therapy in patients with a history of breast cancer: Risks and options. Eur Menopause J 1996;3(2):99–105.

    Google Scholar 

  10. Kenemans P, Scheele F, Burger CW. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence. Eur J Obstet Gynec Reprod Biol 1997; 71:199–203.

    Article  CAS  Google Scholar 

  11. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37.

    PubMed  CAS  Google Scholar 

  12. Ciocca DR, Vargas Roig LM. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocr Reviews 1995;16:35–62.

    CAS  Google Scholar 

  13. Toniolo PO, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190–97.

    Article  PubMed  CAS  Google Scholar 

  14. Negri E, La Vecchia C, Bruzzi P, et al. Risk factors for breast cancer: Pooled results from three Italian case-control studies. Am J Epidemiol 1988;128:1207–15.

    PubMed  CAS  Google Scholar 

  15. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. The Lancet 1992;339:I–15, 71–85.

    Google Scholar 

  16. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomized trials. The Lancet 1996;348:1189–96.

    Article  Google Scholar 

  17. Buchanan RB, Blarney RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986;4:1326–30.

    PubMed  CAS  Google Scholar 

  18. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Endocrin Reviews 1993; 15:17–35.

    CAS  Google Scholar 

  19. Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol 1992;31:167–74.

    Article  PubMed  CAS  Google Scholar 

  20. Wren BG. Hormonal replacement therapy and breast cancer. Eur Menopause J 1995;2:13–19.

    Google Scholar 

  21. Wren BG, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 1996;3:4–12.

    Article  Google Scholar 

  22. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effect of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93–100.

    Article  PubMed  CAS  Google Scholar 

  23. Kenemans P, Stampfer M. Hormone replacement therapy and breast cancer (Guest Editorial). Eur J Obstet Gynec Reprod Biol 1996;67:1–4.

    Article  CAS  Google Scholar 

  24. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 1991;265:1985–90.

    Article  CAS  Google Scholar 

  25. Sillero-Arenas M, Delgado Rodriguez M, Ridigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;72:286–94.

    Google Scholar 

  26. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473–80.

    PubMed  CAS  Google Scholar 

  27. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995;332:1589–93. “Reply to letters to the editor.” N Engl J Med 1995;333:1357–58.

    Article  PubMed  CAS  Google Scholar 

  28. Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesteron replacement therapy. Am J Epidemiol 1989;130:221–228.

    PubMed  CAS  Google Scholar 

  29. Stoll BA. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989;25:1909–13.

    Article  PubMed  CAS  Google Scholar 

  30. Powles TJ, Hickish T, Casey S, et al. Hormone replacement after breast cancer. The Lancet 1993;342:60–61.

    Article  CAS  Google Scholar 

  31. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67–72.

    Article  Google Scholar 

  32. DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: A cohort study. Am J Obstet Gynecol 1996;174:1494–98.

    Article  PubMed  CAS  Google Scholar 

  33. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen replacement therapy in women with a history of breast cancer. Monogr Natl Cancer Inst 1994; 16:153–59.

    PubMed  Google Scholar 

  34. Kenemans P, Barentsen R, van de Weijer P. Alternative treatment in the presence of contraindications. In: Kenemans P, Barentsen R, van de Weijer P, editors. Practical HRT. Bussum, The Netherlands: Medicon Europe B.V., 1995: 157–58.

    Google Scholar 

  35. Kenemans P and von Mensdorff S. Current status of Tamoxifen treatment and cancer risk. CME J Gynec Oncol 1997;1:9–14.

    Google Scholar 

  36. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17-beta estradiol and raloxifene. Science 1996;73:1222–25.

    Article  Google Scholar 

  37. Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 1994;49:311–18.

    Article  PubMed  CAS  Google Scholar 

  38. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med, 1994;331:347–52.

    Article  PubMed  CAS  Google Scholar 

  39. McDonald CC, Alexander FE, Thyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br MedJ 1995;311:977–80.

    Article  CAS  Google Scholar 

  40. Kenemans P. Tamoxifen: Alternative hormone replacement therapy with an anti-oestrogen? Eur Menopause J 1996;3(1):3–5.

    Article  Google Scholar 

  41. Leeuwen F van, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. The Lancet 1994;343:448–52.

    Article  Google Scholar 

  42. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645–51.

    Article  PubMed  CAS  Google Scholar 

  43. Horn-Ross PL. Multiple primary cancers involving the breast. Epidemiol Rev 1993; 15:169–76.

    PubMed  CAS  Google Scholar 

  44. Adami H, Bergström R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cancer 1985;55:643–47.

    Article  PubMed  CAS  Google Scholar 

  45. Kenemans P. Risk profile-based long-term hormone replacement therapy. Eur Menopause J 1995;2(4):3–4.

    Google Scholar 

Download references

Authors
  1. P. Kenemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Scheele
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Pharmacological Sciences, University of Milan, Milan, Italy

    R. Paoletti

  2. Department of Obstetrics and Gynecology, University of Milan, Milan, Italy

    P. G. Crosignani

  3. Department of Obstetrics and Gynaecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    P. Kenemans

  4. Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden

    G. Samsioe

  5. Institute of Pharmacological Sciences, University of Milan, Milan, Italy

    M. R. Soma

  6. Giovanni Lorenzini Medical Foundation, Houston, Texas, USA

    A. S. Jackson (Managing Editor) (Managing Editor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kenemans, P., Scheele, F. (1997). Hormone Replacement Therapy after Breast Cancer. In: Paoletti, R., Crosignani, P.G., Kenemans, P., Samsioe, G., Soma, M.R., Jackson, A.S. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5560-1_34

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5560-1_34

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6343-2

  • Online ISBN: 978-94-011-5560-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation